Clinical Cancer Research

CERo Therapeutics, Inc. Provides Corporate Update for Shareholders

Retrieved on: 
onsdag, maj 15, 2024
Clinical Cancer Research, Patient, Intellectual property, CERO, Cero, Science, Documentation, FDA, Therapy, Neoplasm, SAN, Publication, AML, Growth, Cancer, Molecular Therapy, Communication, Research, CGMP, Toxicology, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq:CERO) (“CERo”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, provides shareholders with a corporate update reviewing activities since its entering the public market.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq:CERO) (“CERo”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, provides shareholders with a corporate update reviewing activities since its entering the public market.
  • CERo Chairman and CEO Brian G. Atwood comments, “CERo has undergone significant transformation since the founding of this small private company dedicated to exploring the potential of engineered T cells, to a merger with SPAC Phoenix Biotech Acquisition Corporation, with multiple preclinical milestones along the way.
  • The June 2023 initiation of the merger, followed by the February 2024 de-SPAC has positioned the Company as an operating Nasdaq-traded entity, which we believe has been in the highest interest of all our various shareholders.
  • In the meantime we have been diligently completing the pre-clinical studies and documentation tasks necessary to initiate clinical trials after acceptance of an Investigational New Drug Application with the FDA.

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update

Retrieved on: 
torsdag, maj 2, 2024
Clinical Cancer Research, SCLC, CRDF, RAS, Trial of the century, Carcinoma, Patient, AACR, Cancer, Bev, PLK1, Ovarian cancer, SAN, Pharmaceutical industry

Company highlights for the quarter ended March 31, 2024 and subsequent weeks include:

Key Points: 
  • Company highlights for the quarter ended March 31, 2024 and subsequent weeks include:
    Presented updated data at AACR Annual Meeting 2024 that supports ongoing first-line RAS-mutated mCRC clinical study.
  • Contingent upon the results, Cardiff Oncology will initiate a Phase 3, randomized trial, CRDF-005, with registrational intent.
  • As of March 31, 2024, Cardiff Oncology had approximately $67.2 million in cash, cash equivalents, and short-term investments.
  • Cardiff Oncology will host a corresponding conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on May 2, 2024.

Crescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first ‘2 in 1’ immune cell engager CB699 at AACR 2024

Retrieved on: 
onsdag, april 10, 2024
PSMA, Institute of Cancer Research, Cancer, MSLN, Clinical Cancer Research, Cancer research, Research, The Institute, Half-life, PD-L1, Prostate cancer, CD137, VH, Therapy, Patient, APC, Toxicity, AACR, Antibody, Annual general meeting, Dynamics (music), Pharmacology, NK

Theodora Harold, CEO at Crescendo Biologics, commented: “Crescendo employs a tumour-targeted approach to directing immune cell activation against cancer.

Key Points: 
  • Theodora Harold, CEO at Crescendo Biologics, commented: “Crescendo employs a tumour-targeted approach to directing immune cell activation against cancer.
  • The data from our two lead programmes highlight the potential of immuno-oncology therapies that are potent and long-lasting, yet well-tolerated by patients.
  • “The pharmacology data we have shared on CB307, underpins its clinical development in PSMA+ metastatic castration-resistant prostate cancer (mCRPC), which continues at pace in our ongoing Phase 1b trial.
  • The details of this research have also been published in Clinical Cancer Research, a journal of the AACR.

Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer

Retrieved on: 
torsdag, april 18, 2024
Oncology, Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Medical school, University, Cancer, The Lancet, Journal of Clinical Oncology, Lung cancer, Clinical Cancer Research, NDA, Pancreatic cancer, Hematology, Internal medicine, RAS, Nektar, Leukemia, Patient, Data management, Northeast Ohio Medical University, Blood, Nektar Therapeutics, Therapy, Journal, Verastem Oncology

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of John Hayslip, M.D., an accomplished oncologist with deep clinical research, development, and commercialization experience, to chief medical officer where he will lead the Company’s clinical and medical strategy.

Key Points: 
  • Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of John Hayslip, M.D., an accomplished oncologist with deep clinical research, development, and commercialization experience, to chief medical officer where he will lead the Company’s clinical and medical strategy.
  • “John is a recognized leader in oncology with broad expertise across cancer research and development, business development and organizational leadership, and we welcome him to the Verastem team,” said Dan Paterson, president and chief executive officer of Verastem Oncology.
  • Dr. Hayslip received his medical degree from Northeast Ohio Medical University and a master’s degree in clinical research from the Medical University of South Carolina.
  • Following his residency in internal medicine, Dr. Hayslip completed his fellowship in hematology-oncology at the Medical University of South Carolina, leading to dual board certifications in both hematology and medical oncology.

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

Retrieved on: 
måndag, mars 25, 2024
Ovarian cancer, Gene, Clinical Cancer Research, Erasmus MC, Data analysis, Colorectal cancer, Progression-free survival, Patient, Neoplasm, Triple-negative breast cancer, Tumor microenvironment, Manuscript, Pancreatic cancer, Cancer, Doctor of Philosophy, MD, Epithelium, PD-L1, AIM, Liver, RNA, Vaccine

The manuscript titled “ Rintatolimod in Advanced Pancreatic Cancer enhances Anti-Tumor Immunity through Dendritic Cell-Mediated T Cell Responses ,” appears in the journal Clinical Cancer Research, one of oncology’s most prestigious journals.

Key Points: 
  • The manuscript titled “ Rintatolimod in Advanced Pancreatic Cancer enhances Anti-Tumor Immunity through Dendritic Cell-Mediated T Cell Responses ,” appears in the journal Clinical Cancer Research, one of oncology’s most prestigious journals.
  • Ampligen is a dsRNA product candidate that acts via the TLR-3 receptor present on several immune cells, epithelial cells and tumors.
  • Post-Ampligen, the increased peripheral abundance of BTLA+XCR1+ cDC1s and CD4+SELL+ T cells correlated with improved clinical outcomes.
  • Additionally, the changes in the tumor microenvironment we see in pancreatic cancer are similar to those we have seen in triple-negative breast cancer, ovarian cancer and colorectal cancer metastatic to the liver.

Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer

Retrieved on: 
tisdag, april 2, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, MSD, Breast cancer, Goserelin, Patient, Lung, Social media, Immunoglobulin G, National Cancer Institute, Neoplasm, Merck & Co., TNBC, Capecitabine, DXD, BRCA, Clinical Cancer Research, Metabolism, Immunology, Biopharmaceutical, World Health Organization, Cancer, Safety, ADC, BLA, Daiichi Sankyo, Vinorelbine, IHC, Mutation, NSCLC, Disease, Merck, AKT, Death, MD, AstraZeneca, PARP, Oncotarget, PFS, FDA, OS, HER2, Eribulin, Cleavage, Progression-free survival, Triple-negative breast cancer, Female, Emerging, Olaparib, Biology, Sapporo Medical University, Medicine, Pharmaceutical industry

The safety profile of datopotamab deruxtecan was consistent with that observed in other ongoing trials with no new safety concerns identified.

Key Points: 
  • The safety profile of datopotamab deruxtecan was consistent with that observed in other ongoing trials with no new safety concerns identified.
  • Additional regulatory submissions for datopotamab deruxtecan in lung and breast cancer are underway globally.
  • A comprehensive global clinical development program is underway with more than 20 trials evaluating the efficacy and safety of datopotamab deruxtecan across multiple cancers, including NSCLC, triple-negative breast cancer (TNBC) and HR-positive, HER2-negative breast cancer.
  • Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer.

Lunit SCOPE IO Reveals Promising Results in Neoadjuvant Immunotherapy Study for Head and Neck Cancer Patients

Retrieved on: 
tisdag, mars 26, 2024
Research, Head, Clinical Cancer Research, Immunotherapy, Patient, Tumor microenvironment, Durvalumab, Cancer, AI, CCR, AACR, Phenotype, Yonsei University, Immune system, Therapy

SEOUL, South Korea, March 26, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the publication of a new study featuring Lunit SCOPE IO, Lunit's AI-powered analyzer for quantitative immune phenotyping from H&E. The study was recently published in Clinical Cancer Research (CCR), an international journal by the American Association for Cancer Research (AACR).

Key Points: 
  • The study was recently published in Clinical Cancer Research (CCR), an international journal by the American Association for Cancer Research (AACR).
  • This investigation addresses the current lack of exploration into the clinical implications of neoadjuvant immunotherapy in HNSCC patients with resectable tumors, utilizing Lunit SCOPE IO to examine the changes in tumor microenvironment when treated with durvalumab and tremelimumab.
  • "Through this prospective clinical study, we have confirmed the clinical utility of preoperative immunotherapy for treating locally advanced head and neck cancer," said Professor Kim Hye Ryun, head of the research.
  • "In this study, Lunit SCOPE IO provides deeper insights into the tumor microenvironment and immune response, empowering healthcare professionals with invaluable information to make more informed treatment decisions.

Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

Retrieved on: 
torsdag, februari 29, 2024
CRDF, SAN, Research, Investment, Cancer, Bev, FOLFIRI, PLK1, Bevacizumab, Standard of care, Clinical Cancer Research, Interim, Safety, Patient, SOC, Pharmaceutical industry

New clinical data from discontinued second-line randomized ONSEMBLE trial provides further evidence of onvansertib’s improvement of the efficacy for standard of care therapy in bev naïve patients.

Key Points: 
  • New clinical data from discontinued second-line randomized ONSEMBLE trial provides further evidence of onvansertib’s improvement of the efficacy for standard of care therapy in bev naïve patients.
  • Contingent upon the results, Cardiff Oncology will initiate a Phase 3, randomized trial, CRDF-005, with registrational intent.
  • Full Year 2023 Financial Results:
    As of December 31, 2023, Cardiff Oncology had approximately $75 million in cash, cash equivalents, and short-term investments.
  • Cardiff Oncology will host a corresponding conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on February 29, 2024.

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

Retrieved on: 
torsdag, mars 7, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Therapy, NSCLC, Investigational New Drug, Bone marrow, AML, RUNX1, Cancer, B-cell lymphoma, ASXL1, Clinical Cancer Research, Classification, Patient, CERO, IND, Cero, Vaccine

The results in the paper found that the target for CER-1236 is found in the large majority (83%) of leukemic cells extracted from the bone marrow from patients, and that more importantly CER-1236 effectively eliminated leukemic cells in the company’s experiments.

Key Points: 
  • The results in the paper found that the target for CER-1236 is found in the large majority (83%) of leukemic cells extracted from the bone marrow from patients, and that more importantly CER-1236 effectively eliminated leukemic cells in the company’s experiments.
  • Finally, the target for CER-1236 was found by CERo to be highly expressed and detectable across common AML genetic classification subtypes, including patient samples with adverse risk mutations in TP53, ASXL1 and RUNX1.
  • “We’re very pleased with this publication in Clinical Cancer Research supporting our near term plans to advance CER-1236 into the clinic.
  • As we have previously reported, CERo plans to file an Investigational New Drug (IND) application in the first half of 2024, and is targeting initial treatment of AML patients as well as B Cell lymphoma patients before the end of the year,” said Brian G Atwood, CERo’s Chairman and Chief Executive Officer.

Jennifer Rider Appointed ConcertAI Head of Real-World Evidence Services

Retrieved on: 
tisdag, januari 30, 2024
Real-World Evidence, Abstract, Interview, Oncology, Research, AI, Clinical Cancer Research, Public, Flexner Report, FDA, Publication, Public health, Aetion, RCT, RWE, Harvard University, Epidemiology, MPH, Doctor of Science, Harvard Medical School, Drug development, Health, Doctor of Philosophy, University, University of Wisconsin–Madison, RWD

CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ -- ConcertAI, the leader in oncology Real-World Data (RWD) and AI SaaS Solutions and for healthcare and life sciences, today announced Jennifer Rider, ScD, MPH, as the leader of the company's Real-World Evidence Services, focusing on regulatory applications of RWD as part of registration trials, breakthrough designation solutions post-approval studies, and regulatory registries. 

Key Points: 
  • Dr. Rider has over 20 years of experience in cancer epidemiology and real-world evidence research.
  • She first joined ConcertAI in 2020, moving from there to lead Aetion's Oncology Center of Excellence.
  • "Real-world evidence has taken on a more formal role in regulatory decision-making with the FDA's formalization of their guidance late last year ," said Jeff Elton, PhD, CEO of ConcertAI.
  • To hear more from Jennifer directly, listen to her interview on the latest episode of The ConcertAI Podcast here .